Phase II study of irinotecan in patients with chemotherapy pretreated angiosarcoma. The ANGIRI study.
Phase 2
Recruiting
- Conditions
- Angiosarcoma
- Registration Number
- JPRN-UMIN000002805
- Lead Sponsor
- Masashi Ando
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
1. Expected women 2. patients withj active infection 3. patients with interstitial pneumonia 4. patients with symptomatic brain metastasis 5. HIV positive patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method